Effect of cyclic AMP on the cell cycle regulation of ribonucleotide reductase M2 subunit messenger RNA concentrations in wild-type and mutant S49 T lymphoma cells.
Ribonucleotide reductase activity in S49 T lymphoma cells is cell cycle regulated by de novo protein synthesis of the M2 subunit. There is maximal enzyme activity in S and G2/M phase with low activity and low concentrations of the M2 subunit in G1 phase. Pharmacologic concentrations of cyclic AMP arrest S49 cells in the G1 phase of the cell cycle. We investigated the effect of cyclic AMP on M2 messenger RNA concentrations using RNA from exponentially growing and elutriated, cell cycle-enriched populations. To discern whether cyclic AMP-induced G1 arrest was associated with low concentrations of M2-specific messenger RNA, we probed blots with a full-length cDNA for M2. Cell cycle variation in M2 messenger RNA concentrations was similar in wild-type, hydroxyurea-resistant cells with amplified M2 activity, and cyclic AMP-dependent protein kinase-deficient cell lines. All lines had low amounts of M2-specific mRNA in early G1, an increase at the late G1/early S phase interface, a decrease in mid S phase, and another increase in late S phase that continued through G2/M. These concentrations did not directly correlate with enzyme activity, suggesting other regulatory effects might participate in determining ribonucleotide reductase activity. Cyclic AMP exposure appeared to induce cell cycle arrest in early G1 with low M2-specific messenger RNA concentration. This effect reversed upon washout of the cyclic AMP and was dependent on functional cyclic AMP-dependent protein kinase (PKA). These results suggest that cyclic AMP arrests S49 mouse T lymphoma cells in early G1 prior to transcriptional activation of the M2 gene.
Albert
D A
DA
Department of Medicine, University of Chicago, Illinois 60637.
Nodzenski
E
E
Yim
G
G
Kowalski
J
J
D000818:Animals; D015152:Blotting, Northern; D002453:Cell Cycle / Q000187:drug effects*; D002460:Cell Line; D000242:Cyclic AMP / Q000494:pharmacology*; D004351:Drug Resistance; D006918:Hydroxyurea / Q000494:pharmacology; D066298:In Vitro Techniques; D051379:Mice; D011494:Protein Kinases / Q000502:physiology; D012333:RNA, Messenger / Q000235:genetics; D012264:Ribonucleotide Reductases / Q000235:genetics* / Q000378:metabolism; D013601:T-Lymphocytes / Q000502:physiology*; D014158:Transcription, Genetic / Q000187:drug effects; D014407:Tumor Cells, Cultured
D012333:RNA, Messenger; D000242:Cyclic AMP; D012264:Ribonucleotide Reductases; D011494:Protein Kinases; D006918:Hydroxyurea